Credit: ViiV Healthcare. The new blister pack is a monthly 30-count box containing 5 sheets of tablets; each sheet is perforated and is about "the size of a credit card" offering more discreet ...

Previously, Dovato was only approved for treatment-naïve adults. The Food and Drug Administration (FDA) has expanded the approval of Dovato (dolutegravir/lamivudine ...

Previous clinical results for ViiV Healthcare’s vaunted two-drug HIV regimens have yet to pose a big threat to chief rival Gilead Sciences. But the GlaxoSmithKline joint venture aims to change that ...

In a landmark win for GlaxoSmithKline’s ViiV Healthcare and its ambition to reduce the number of medications HIV patients are taking—and beat rival Gilead Sciences along the way—the FDA has approved ...

Roughly 1.1 million people in the U.S. live with HIV with 15 percent of that population unaware they are infected. Treating these individuals must be highly effective to suppress the viral load in the ...

In largest head-to-head randomized clinical trial evaluating the two medicines, Dovato (DTG/3TC) met the primary endpoint, demonstrating sustained non-inferior efficacy versus Biktarvy (BIC/FTC/TAF) ...

Findings showed 26 of the 30 participants achieved and maintained viral suppression (HIV-1 RNA 50c/mL) at week 48. The Food and Drug Administration (FDA) has expanded ...

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer Inc. and Shionogi Limited as shareholders, today presented three-year results from the ...

(Reuters) - GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a ...

GlaxoSmithKline plc’s GSK HIV subsidiary, ViiV Healthcare, announced that the late-stage study, evaluating its newly approved single-tablet two-drug HIV regimen of Dovato met the primary endpoint. The ...